Contemporary data indicate that patients with signs and symptoms of ischaemia and non-obstructive coronary artery disease (INOCA) often have coronary microvascular dysfunction (CMD) with elevated risk for adverse outcomes. Coronary endothelial (constriction with acetylcholine) and/or microvascular (limited coronary flow reserve with adenosine) dysfunction are well-documented, and extensive non-obstructive atherosclerosis is often present. Despite these data, patients with INOCA currently remain under-treated, in part, because existing management guidelines do not address this large, mostly female population due to the absence of evidence-based data. Relatively small sample-sized, short-term pilot studies of symptomatic mostly women, with INOCA, using intense medical therapies targeting endothelial, microvascular, and/or atherosclerosis mechanisms suggest symptom, ischaemia, and coronary vascular functional improvement, however, randomized, controlled outcome trials testing treatment strategies have not been completed. We review evidence regarding CMD pharmacotherapy. Potent statins in combination with angiotensin-converting enzyme inhibitor (ACE-I) or receptor blockers if intolerant, at maximally tolerated doses appear to improve angina, stress testing, myocardial perfusion, coronary endothelial function, and microvascular function. The Coronary Microvascular Angina trial supports invasive diagnostic testing with stratified therapy as an approach to improve symptoms and quality of life. The WARRIOR trial is testing intense medical therapy of high-intensity statin, maximally tolerated ACE-I plus aspirin on longer-term outcomes to provide evidence for guidelines. Novel treatments and those under development appear promising as the basis for future trial planning.
Keywords: Angina; CMD; Ischaemia; Women; INOCA.
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: email@example.com.
A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.Eur Heart J. 2016 May 14;37(19):1504-13. doi: 10.1093/eurheartj/ehv647. Epub 2015 Nov 27. Eur Heart J. 2016. PMID: 26614823 Free PMC article. Clinical Trial.
Enhanced External Counterpulsation (EECP): An Evidence-Based Analysis.Ont Health Technol Assess Ser. 2006;6(5):1-70. Epub 2006 Mar 1. Ont Health Technol Assess Ser. 2006. PMID: 23074496 Free PMC article.
Women's health: making cardiovascular disease real.Curr Opin Cardiol. 2018 Sep;33(5):506-513. doi: 10.1097/HCO.0000000000000544. Curr Opin Cardiol. 2018. PMID: 29985202 Free PMC article. Review.
Experimental animal models of coronary microvascular dysfunction.Cardiovasc Res. 2020 Mar 1;116(4):756-770. doi: 10.1093/cvr/cvaa002. Cardiovasc Res. 2020. PMID: 31926020 Free PMC article.
How to Diagnose and Manage Angina Without Obstructive Coronary Artery Disease: Lessons from the British Heart Foundation CorMicA Trial.Interv Cardiol. 2019 May 21;14(2):76-82. doi: 10.15420/icr.2019.04.R1. eCollection 2019 May. Interv Cardiol. 2019. PMID: 31178933 Free PMC article. Review.
Cited by 2 articles
COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.Cardiovasc Res. 2020 Apr 30:cvaa106. doi: 10.1093/cvr/cvaa106. Online ahead of print. Cardiovasc Res. 2020. PMID: 32352535 Free PMC article.
Coronary microvascular disease: the next frontier for Cardiovascular Research.Cardiovasc Res. 2020 Mar 1;116(4):737-740. doi: 10.1093/cvr/cvaa035. Cardiovasc Res. 2020. PMID: 32149331 No abstract available.